MD20140107A2 - Anticorpi împotriva metaloproteinazei 9 din matrice - Google Patents

Anticorpi împotriva metaloproteinazei 9 din matrice

Info

Publication number
MD20140107A2
MD20140107A2 MDA20140107A MD20140107A MD20140107A2 MD 20140107 A2 MD20140107 A2 MD 20140107A2 MD A20140107 A MDA20140107 A MD A20140107A MD 20140107 A MD20140107 A MD 20140107A MD 20140107 A2 MD20140107 A2 MD 20140107A2
Authority
MD
Moldova
Prior art keywords
antibodies
matrix metalloproteinase
mmp9
functional fragment
binding proteins
Prior art date
Application number
MDA20140107A
Other languages
English (en)
Russian (ru)
Inventor
Виктория СМИТ
Скотт МакКОЛИ
Original Assignee
Gilead Biologics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Biologics, Inc. filed Critical Gilead Biologics, Inc.
Publication of MD20140107A2 publication Critical patent/MD20140107A2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24035—Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Invenţia se referă la imunologie, în special la compoziţii şi metode de utilizare a lor, care implică proteine de legare, de exemplu anticorpi şi fragmente de legare a antigenului acestora, care se leagă de metaloproteinaza matriceală-9 (MMP9) (MMP9 este cunoscută şi ca gelatinaza-B), cum ar fi în cazul în care proteinele de legare cuprind un lanţ imunoglobulinic greu (Ig) (fragmentul funcţional al acestuia) şi un lanţ uşor Ig (fragmentul funcţional al acestuia).
MDA20140107A 2012-02-29 2012-02-29 Anticorpi împotriva metaloproteinazei 9 din matrice MD20140107A2 (ro)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/027160 WO2013130078A1 (en) 2012-02-29 2012-02-29 Antibodies to matrix metalloproteinase 9

Publications (1)

Publication Number Publication Date
MD20140107A2 true MD20140107A2 (ro) 2015-03-31

Family

ID=45816000

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20140107A MD20140107A2 (ro) 2012-02-29 2012-02-29 Anticorpi împotriva metaloproteinazei 9 din matrice

Country Status (23)

Country Link
US (4) US9550836B2 (ro)
EP (1) EP2820048B1 (ro)
JP (1) JP6067756B2 (ro)
KR (1) KR20140130724A (ro)
CN (1) CN104395345A (ro)
AP (1) AP2014007907A0 (ro)
AU (4) AU2012318302C1 (ro)
BR (1) BR112014021477A2 (ro)
CA (1) CA2865530C (ro)
CL (1) CL2014002282A1 (ro)
CO (1) CO7061040A2 (ro)
CR (1) CR20140443A (ro)
EA (1) EA201491575A1 (ro)
EC (1) ECSP14020504A (ro)
ES (1) ES2731441T3 (ro)
HK (2) HK1205153A1 (ro)
IN (1) IN2014DN08011A (ro)
MD (1) MD20140107A2 (ro)
MX (1) MX2014010449A (ro)
PH (1) PH12014501931A1 (ro)
SG (1) SG11201405305PA (ro)
WO (1) WO2013130078A1 (ro)
ZA (1) ZA201406319B (ro)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2739505T3 (es) 2010-08-27 2020-01-31 Gilead Biologics Inc Anticuerpos contra la metaloproteinasa 9 de la matriz
CN104271156B (zh) 2012-02-29 2017-06-16 吉利德生物制剂公司 抗基质金属蛋白酶9的抗体
AP2014007907A0 (en) 2012-02-29 2014-08-31 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
TW201544511A (zh) * 2014-02-27 2015-12-01 Gilead Sciences Inc 針對基質金屬蛋白酶９之抗體及其使用方法
EP2985295A1 (en) 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
EP2985296A1 (en) 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
CN105037553B (zh) * 2015-08-20 2018-04-17 内蒙古蒙元生物基因科技有限公司 一种能够检测癌症的免疫球蛋白
AU2017248354A1 (en) 2016-04-08 2018-10-04 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
US10326830B1 (en) * 2016-09-02 2019-06-18 Amazon Technologies, Inc. Multipath tunneling to a service offered at several datacenters
US10894837B2 (en) 2016-12-16 2021-01-19 Université De Bordeaux MMP9 inhibitors and uses thereof in the prevention or treatment of a depigmenting disorder
US10941178B2 (en) 2017-03-17 2021-03-09 Gilead Sciences, Inc. Method of purifying an antibody
WO2019017338A1 (ja) 2017-07-18 2019-01-24 第一三共株式会社 活性型ｍｍｐ－９結合ペプチド
CN110885375B (zh) * 2019-12-20 2021-07-02 南京融捷康生物科技有限公司 特异性针对mmp-9蛋白锌离子结合结构域的单域抗体及产品与应用
CN111785321B (zh) * 2020-06-12 2022-04-05 浙江工业大学 一种基于深度卷积神经网络的dna绑定残基预测方法
CN117327186B (zh) * 2023-07-12 2024-03-12 北京达成生物科技有限公司 结合mmp3蛋白的双特异性抗体及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
WO2001004157A2 (en) * 1999-07-13 2001-01-18 University Of Southern California NOVEL METHOD AND COMPOSITION FOR INHIBITION OF ANGIOGENESIS USING ANTAGONISTS BASED ON MMP-9 AND β1 INTEGRINS
CN1459505A (zh) * 2002-05-21 2003-12-03 赵平 中国汉族人基质金属蛋白酶－9基因重构、表达、纯化及其医学应用
JP4601426B2 (ja) * 2002-09-06 2010-12-22 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体成分ｃ５に対する抗体を使用する喘息の処置の方法
KR101434682B1 (ko) * 2005-12-02 2014-08-27 제넨테크, 인크. 결합 폴리펩티드 및 이들의 용도
AR066913A1 (es) * 2007-06-08 2009-09-23 Irm Llc Metodos y composiciones para inducir la apoptosis en celulas cancerosas
WO2009111508A2 (en) * 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
WO2009111450A2 (en) * 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 binding proteins
US20110262396A1 (en) * 2008-10-22 2011-10-27 Dyax Corp. Combination treatments comprising protease binding proteins for inflammatory disorders
US20110286916A1 (en) * 2008-11-20 2011-11-24 Jose Miguel Aste-Amezaga Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
WO2011092700A1 (en) * 2010-01-27 2011-08-04 Yeda Research And Development Co. Ltd. Antibodies that inhibit metalloproteins
ES2739505T3 (es) * 2010-08-27 2020-01-31 Gilead Biologics Inc Anticuerpos contra la metaloproteinasa 9 de la matriz
AP2014007907A0 (en) 2012-02-29 2014-08-31 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
CN104271156B (zh) 2012-02-29 2017-06-16 吉利德生物制剂公司 抗基质金属蛋白酶9的抗体

Also Published As

Publication number Publication date
AU2017216508B2 (en) 2019-03-07
MX2014010449A (es) 2015-02-10
US20170183421A1 (en) 2017-06-29
JP2015514394A (ja) 2015-05-21
AU2017261626A1 (en) 2017-12-07
AP2014007907A0 (en) 2014-08-31
PH12014501931A1 (en) 2014-11-24
US20210054101A1 (en) 2021-02-25
JP6067756B2 (ja) 2017-01-25
AU2012318302C1 (en) 2017-06-15
EP2820048B1 (en) 2019-04-17
HK1208036A1 (en) 2016-02-19
NZ629888A (en) 2017-02-24
EP2820048A1 (en) 2015-01-07
CA2865530A1 (en) 2013-09-06
SG11201405305PA (en) 2014-09-26
KR20140130724A (ko) 2014-11-11
CN104395345A (zh) 2015-03-04
ZA201406319B (en) 2016-02-24
CR20140443A (es) 2014-11-17
US20190127486A1 (en) 2019-05-02
US11634505B2 (en) 2023-04-25
US9550836B2 (en) 2017-01-24
US20150140580A1 (en) 2015-05-21
CL2014002282A1 (es) 2015-02-20
WO2013130078A1 (en) 2013-09-06
CO7061040A2 (es) 2014-09-19
HK1205153A1 (en) 2015-12-11
AU2017216508A1 (en) 2017-08-31
IN2014DN08011A (ro) 2015-05-01
CA2865530C (en) 2019-02-19
AU2015242967B2 (en) 2017-08-24
ECSP14020504A (es) 2015-09-30
AU2012318302B2 (en) 2016-08-18
ES2731441T3 (es) 2019-11-15
US10800857B2 (en) 2020-10-13
AU2012318302A1 (en) 2013-09-19
EA201491575A1 (ru) 2015-01-30
BR112014021477A2 (pt) 2018-06-12
AU2015242967A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
MD20140108A2 (ro) Anticorpi împotriva metaloproteinazei 9 matriciale
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
MD20140107A2 (ro) Anticorpi împotriva metaloproteinazei 9 din matrice
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
PH12014502527B1 (en) St2 antigen binding proteins
EA201491214A1 (ru) Композиции и способы применения антител, нацеленных на фактор p
EP4356927A3 (en) Antibody based reagents that specifically recognize toxic oligomeric forms of tau
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
MX2017001959A (es) Anticuerpos especificos para mmp9.
MX2015005719A (es) Terapias de combinacion que usan moleculas de union anti-psl y pcrv de pseudomonas.
EA201291065A1 (ru) Антитела против vla-4
EA201990895A1 (ru) Антитела к о1 и варианты их применения
EA201590918A1 (ru) Антитела к bmp-6
MX2016011177A (es) Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos.
CL2010000521A1 (es) Anticuerpo aislado o fragmento que bloquea la fijacion de la union de la proteina wise; secuencias de cdr de la cadena liviana y pesada; polipeptido inmunogenico de wise; composicion farmaceutica que comprende dicho anticuerpo.

Legal Events

Date Code Title Description
FA9A Abandonment or withdrawal of application (patent for invention)